| Literature DB >> 22202669 |
Alessio La Manna1, Alessandra Sanfilippo, Davide Capodanno, Antonella Salemi, Gesualdo Polizzi, Wanda Deste, Glauco Cincotta, Alessandra Cadoni, Anna Marchese, Michele Figuera, Gian P Ussia, Rosetta Pittalà, Carmelo Privitera, Corrado Tamburino.
Abstract
BACKGROUND: Before trans-catheter aortic valve implantation (TAVI), assessment of cardiac function and accurate measurement of the aortic root are key to determine the correct size and type of the prosthesis. The aim of this study was to compare cardiovascular magnetic resonance (CMR) and trans-thoracic echocardiography (TTE) for the assessment of aortic valve measurements and left ventricular function in high-risk elderly patients submitted to TAVI.Entities:
Mesh:
Year: 2011 PMID: 22202669 PMCID: PMC3271968 DOI: 10.1186/1532-429X-13-82
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Figure 1Aortic valve area measurement by trans-thoracic echocardiography (TTE) and cardiovascular magnetic resonance (CMR). Aortic valve area measured by continuity equation TTE approach: Left ventricular outflow tract (LVOT) diameter (A); transaortic peak velocity (B); aortic velocity-time integral (C). Oblique sagittal view of the aortic outflow tract, with the CMR slice position indicated by three white lines orthogonal to the stenotic jet (D). Oblique transaxial view of the aortic outflow tract, with CMR slice position indicated by three white lines (E). Cross-sectional view of a severely stenotic aortic valve; the white line denotes the aortic valve area (F).
Figure 2Study flow chart. Reasons for excluding patients from cardiovascular magnetic resonance or trans-thoracic echocardiography.
Patients Characteristics
| Patients | 49 |
|---|---|
| Male, n (%) | 21 (42.9) |
| Age, (mean ± DS) | 80.8 ± 4.8 |
| Log EuroScore, (mean ± DS) | 14.9 ± 9.3 |
| BMI, (mean ± DS) | 27.6 ± 5.2 |
| Syncope, n (%) | 11 (22.4) |
| Unstable Angina, n (%) | 16 (32.7) |
| Hospitalization for heart failure, n (%) | 16 (32.7) |
| Dyspnoea, n (%) | 42 (85.7) |
| Diabetes, n (%) | 7 (14.3) |
| Hypercholesterolemia, n (%) | 21 (42.9) |
| Smoker, n (%) | 7 (14.3) |
| Ex smoker, n (%) | 6 (12.2) |
| History of CAD, n (%) | 11 (22.4) |
| Cirrhosis, n (%) | 1 (2) |
| Renal failure (creatinine > 2 mg/dL), n (%) | 6 (12.2) |
| COPD, n (%) | 15 (30.6) |
| Chronic obstructive arterial disease, n (%) | 2 (4.1) |
| Previous CABG, n (%) | 3 (6.1) |
| Previous PCI, n (%) | 19 (38.7) |
| Previous MI, n (%) | 10 (20.4) |
| Previous TIA, n (%) | 6 (12.2) |
| Previous Stroke, n (%) | 4 (8.2) |
BMI: body mass index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; CABG: coronary artery by-pass graft; PCI: percutaneous coronary intervention; MI: myocardial infarction; TIA: transient ischemic attack.
Figure 3Scattered plot of trans-thoracic echocardiography (TTE) and cardiovascular magnetic resonance (CMR). Correlation analysis of aortic annulus (A), left ventricular outflow tract (LVOT) (B), left ventricular ejection fraction (LVEF) (C) and aortic valve area (AVA) (D) measured by TTE and CMR.
Correlation between TTE and CMR
| Regression Equation | R2 | P | |
|---|---|---|---|
| EDV (ml) | y = 10.8264 + 0.6053 x | 0.50 | < 0.001 |
| ESV (ml) | y = 16.0854 + 0.5269 x | 0.57 | < 0.001 |
| EF (%) | y = 23.9774 + 0.4687 x | 0.47 | < 0.001 |
| LVOT (mm) | y = 7.3743 + 0.6149 x | 0.62 | < 0.001 |
| Ascending aorta (mm) | y = 4.4615 + 0.9059 x | 0.75 | < 0.001 |
| Annulus (mm) | y = 7.1490 + 0.6025 x | 0.48 | < 0.001 |
| Sinus of Valsalva (mm) | y = 7.0782 + 0.7619 x | 0.58 | < 0.001 |
| Sinotubular junction (mm) | y = 4.1418 + 0.8444 x | 0.59 | < 0.001 |
| AVA (cm2) | y = 0.2931 + 0.4723 x | 0.24 | < 0.001 |
| Peak velocity (m/s) | 0.28 | < 0.001 |
TTE: trans-thoracic echocardiography; CMR: cardiovascular magnetic resonance; EDV: end diastolic volume; ESV: end-systolic volume EF: ejection fraction; LVOT: left ventricular outflow tract; AVA: aortic valve area.
Comparison between TTE and CMR measurements
| TTE | CMR | P | |
|---|---|---|---|
| EDV (ml) | 103.6 ± 41.4 | 153.3 ± 48 | < 0.001 |
| ESV (ml) | 50.3 ± 29.2 | 64.9 ± 42 | < 0.001 |
| EF (%) | 52.1 ± 10.1 | 60.1 ± 14.8 | < 0.001 |
| LVOT (mm) | 19.8 ± 2.08 | 20.3 ± 2.6 | < 0.001 |
| Ascending aorta (mm) | 35.8 ± 4.1 | 34.5 ± 3.9 | < 0.001 |
| Annulus (mm) | 21.4 ± 1.9 | 23.7 ± 2.2 | < 0.001 |
| Sinus of Valsalva (mm) | 30.5 ± 3.3 | 30.7 ± 3.3 | < 0.001 |
| Sinotubular junction (mm) | 26.3 ± 3.3 | 26.3 ± 3.0 | < 0.001 |
| AVA (cm2) | 0.64 ± 0.17 | 0.74 ± 0.18 | < 0.001 |
| Peak velocity (m/s) | 3.9 ± 0.8 | 4.7 ± 0.6 | < 0.001 |
TTE: trans thoracic echocardiography; CMR: cardiovascular magnetic resonance; EDV: end diastolic volume; ESV: end-systolic volume; EF: ejection fraction; LVOT: left ventricular outflow tract; AVA: aortic valve area.
Figure 4Agreement of trans-thoracic echocardiography (TTE) and cardiovascular magnetic resonance (CMR) by Bland-Altman analysis. Bland-Altman analysis for aortic annulus (A), left ventricular outflow tract (LVOT) (B), left ventricular ejection fraction (LVEF) (C) and aortic valve area (AVA) (D) measured by TTE and CMR.